HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe

Abstract

The members the EuroSIDA study group are given in the Appendix.

Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study

“…Compared with the highly varied reported incidence of HCV reinfection from 0% to 17% in HIV-positive patients, the incidence of HCV reinfection in our patients with treatment-induced SVR 12 was 4.02 per 100 PYFU, which was in line with a recent large-scale pan-Europe survey that demonstrated an overall incidence of HCV reinfection of 4.65 per 100 PYFU in HIV-positive patients who achieved SVR with IFN or DAA [ 21 ]. Because most patients were MSM, we further demonstrated the risk of HCV reinfection in our HIV-positive MSM to be 4.12 per 100 PYFU, which was also similar to a long-term cohort that reported an incidence of 3.85 per 100 PYFU in the Netherlands [ 18 ].…”

“…Although the risk of HCV reinfection of our HIV-positive patients was much higher than that of the reference patients, we found that no baseline factors predicted HCV reinfection [ 21 ]. Multiple sex partners, unprotected anal intercourse, group sex, sharing sex toys, and amphetamine abuse in HIV-positive MSM and ongoing use of cocaine, methamphetamine, or heroin injection in HIV-positive PWID after achieving SVR were highly associated with HCV reinfection; these factors were evident in our HIV-positive patients with HCV reinfection [ 17 , 20 , 24 , 30 ].…”

“…While most Western studies have demonstrated decreasing incidence rates of HCV reinfection in HIV-positive patients following the implementation of HCV screening and DAA treatment scale-up after 2014, the secular trend of HCV reinfection tended to increase in our HIV-positive patients after 2015, when DAAs were made available in Taiwan [ 15 , 16 , 18 , 21 , 32 ]. Several factors may contribute to the divergent trends of HCV reinfection.…”

“…The reported risks of HCV reinfection in HIV/HCV-coinfected patients with treatment-induced SVR 12 varied significantly among Western studies, ranging from 0% to 17.0% per 100 person-years of follow-up (PYFU) [ 14–22 ]. Moreover, several studies have shown a decrease in the incidence of HCV reinfection following the widespread use of DAAs [ 15 , 16 , 18 , 21 ]. Data regarding HCV reinfection in East Asians with HIV/HCV coinfection who achieved SVR 12 with anti-HCV treatment were limited.…”

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects

“…However, γδ T- and B-cell activation remained at higher levels in HIV-HCV co-infection than that which was measured in HCV mono-infection alone. Given the enduring clinical risk of cART-treated HIV-infected subjects [ 23 ] and the high rates of subsequent HCV re-infection in this population [ 30 ], future studies are needed to elucidate the impact of DAA therapy on long-term immune imbalances in HIV-HCV co-infected individuals.…”